SPAIN: High Levels of HIV Drug Cause Mental Problems

Important note: Information in this article was accurate in 2005. The state of the art may have changed since the publication date.

SPAIN: High Levels of HIV Drug Cause Mental Problems

Reuters (12.13.05) - Thursday, December 15, 2005

In Spain, researchers studying long-term efavirenz therapy found that patients at higher doses had an increased rate of adverse psychiatric events, new research suggests.

Up to half of patients on long-term efavirenz therapy may experience mental disorders, but data are lacking on which patients are at risk, noted Felix Gutierrez, of the Hospital General Universitario de Elche in Alicante, and colleagues.

Researchers evaluated 17 patients on efavirenz-containing regimens who had no history of mental illness. They assessed patients every three months for 18 months, and they tested efavirenz levels five times.

Ten patients experienced mental issues during the study, with sleeping problems being the most common. In four patients, moderate to severe side effects included depression (two patients), mood and concentration/attention problems (one) and obsessive disorder (one). All four discontinued efavirenz.

Patients' efavirenz blood levels ranged from 0.62 to 12.59 micrograms/milliliter, with a 2.74 level being highly predictive for mental disturbances, researchers found. Patients with efavirenz blood levels above 2.74 micrograms/milliliter had a five-fold greater risk of central nervous system side effects than other patients.

Studies have shown efavirenz levels above 1 microgram/milliliter may be adequate to suppress HIV, so "there may be room for dose reduction to avoid [side effects] in selected cases," wrote authors. However, patients in whom other regimens have failed may require blood levels above 3 micrograms/milliliter, they added.

"Future studies are needed to assess whether therapeutic drug monitoring will result in a decrease in the percentage of patients developing [mental problems] while receiving efavirenz-containing regimens with no loss of efficacy," the authors reported.

The full study, "Prediction of Neuropsychiatric Adverse Events Associated with Long-Term Efavirenz Therapy, Using Plasma Drug Level Monitoring," was published in Clinical Infectious Diseases (2005;41:1648-1653).
051215
AD052527

Copyright © 2005 - Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Elton John AIDS Foundation, the National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.

Always watch for outdated information. This article first appeared in 2005. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2005. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.